Literature DB >> 17890940

Pharmacokinetic-pharmacodynamic crisis in the elderly.

Ehab S ElDesoky1.   

Abstract

Aging is characterized by a progressive loss of functional capacities of most if not all organs, a reduction in homeostatic mechanisms, and a response to receptor stimulation. Also, loss of water content and an increase of fat content in the body are reported. Therefore, understanding the influence of age-dependent changes in composition and function of the body on the pharmacokinetics and pharmacodynamics of drugs is important before prescribing drugs to elderly patients. In this study, a Medline search for articles published in the period between 1975 and June 2006 was conducted with use of the key words aging, pharmacokinetics, and pharmacodynamics to review data related to alteration in pharmacokinetics and pharmacodynamics in elderly patients. Analysis of data revealed that the most important pharmacokinetic changes in old age include a decrease in the excretory capacity of the kidney more than the decline in the rate of hepatic drug metabolism. On the other hand, pharmacodynamic changes in the elderly are frequent and commonly ascribed to alteration in the sensitivity to drugs, irrespective of changes in drug disposition. For instance, the sensitivity of the cardiovascular system to beta-adrenergic agonists and antagonists decreases in old age, and the incidence of orthostatic episodes in response to drugs that lower blood pressure increases. However, the central nervous system becomes vulnerable in the elderly to agents that affect brain function (eg, opioids, benzodiazepines, and psychotropic drugs). Therefore, these drugs must be used very cautiously in this age group. In conclusion, the complexity of the interactions between polypharmacy, comorbidity, altered pharmacodynamic sensitivity, and even modest changes in pharmacokinetics in elderly necessitate the medical approach "start low and go slow" for aged subjects, especially if drug therapy is considered beneficial or absolutely necessary for them.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890940     DOI: 10.1097/01.mjt.0000183719.84390.4d

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  53 in total

1.  The incidence of potential drug-drug interactions in elderly patients with arterial hypertension.

Authors:  Vesna Bacic-Vrca; Srecko Marusic; Viktorija Erdeljic; Slaven Falamic; Nives Gojo-Tomic; Dario Rahelic
Journal:  Pharm World Sci       Date:  2010-10-05

2.  Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.

Authors:  Mona Darwish; Mary Kirby; Edward T Hellriegel; Ronghua Yang; Philmore Robertson
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

3.  Adverse drug reactions in a population of hospitalized very elderly patients.

Authors:  Balamurugan Tangiisuran; J Graham Davies; Juliet E Wright; Chakravarthi Rajkumar
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 4.  The blood-brain barrier: geriatric relevance of a critical brain-body interface.

Authors:  Neer Zeevi; Joel Pachter; Louise D McCullough; Leslie Wolfson; George A Kuchel
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

5.  Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.

Authors:  R L Smith; T Haslemo; H Refsum; E Molden
Journal:  Eur J Clin Pharmacol       Date:  2016-06-29       Impact factor: 2.953

Review 6.  Myopathy in older people receiving statin therapy: a systematic review and meta-analysis.

Authors:  Roli B Iwere; Jonathan Hewitt
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

Review 7.  Aging and antihypertensive medication-related complications in the chronic kidney disease patient.

Authors:  Zachary A Marcum; Linda F Fried
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-09       Impact factor: 2.894

8.  High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.

Authors:  A M Sandqvist; D Henrohn; J Schneede; M Hedeland; H C Egeröd; U G Bondesson; B G Wikström
Journal:  Eur J Clin Pharmacol       Date:  2012-06-26       Impact factor: 2.953

9.  Identifying and Implementing Endpoints for Geriatric Mice.

Authors:  Linda A Toth
Journal:  Comp Med       Date:  2018-11-28       Impact factor: 0.982

Review 10.  Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.

Authors:  Robert L Page; Sunny A Linnebur; Lucinda L Bryant; J Mark Ruscin
Journal:  Clin Interv Aging       Date:  2010-04-07       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.